Formulation And Evaluation of Moringa-Based Herbal Tea Powder for Stress Management and Cognitive Health

1.1 Background and Rationale

Anyone who has sat down to study before an important examination and found their mind stubbornly refusing to retain what their eyes are reading has experienced, in the most personal way possible, what sustained stress does to the human brain. The experience is not merely psychological — it is the direct biological consequence of a well-characterised neurological cascade. When the brain perceives a threat, whether physical, emotional, or academic, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the anterior pituitary to secrete adrenocorticotropic hormone (ACTH). ACTH then acts on the adrenal cortex to trigger cortisol release — the body's primary stress hormone.

In small doses, cortisol is genuinely useful. It sharpens attention, mobilises glucose reserves, and helps the body respond to demanding circumstances. But when the stressor is chronic — as it is for millions of students, healthcare workers, and caregivers in the twenty-first century — the sustained elevation of cortisol begins to cause measurable structural and functional harm. It suppresses hippocampal neurogenesis, disrupts long-term potentiation (the molecular basis of memory consolidation), downregulates brain-derived neurotrophic factor (BDNF), promotes neuroinflammation through NF-kB activation, and depletes synaptic serotonin and dopamine. The result is a predictable pattern of cognitive decline, emotional dysregulation, and physical exhaustion that progressively compromises quality of life.

The World Health Organization estimates that stress-related mental health conditions affect well over 450 million people globally. [18] Anxiety disorders alone are among the leading causes of disability worldwide. In India, surveys suggest that over 70% of adults report significant stress impacts on their daily functioning. The conventional pharmaceutical response — benzodiazepines for acute anxiety, SSRIs for chronic anxiety and depression, modafinil-type stimulants for cognitive fatigue — provides partial symptomatic relief but carries a well-

Known Constellation Of Adverse Effects:

physical dependence, withdrawal syndromes, emotional blunting, and the social stigma that continues to surround psychiatric medication use.

This has directed growing scientific attention toward plant-based adaptogens — a category of botanicals defined by their ability to help the body resist and recover from biological, physical, and psychological stressors without disturbing normal homeostatic function. Unlike sedatives or stimulants, adaptogens do not force the neuroendocrine system in a single direction. Instead, they facilitate a recalibration toward balance — normalising HPA axis overactivity, rebuilding neurotransmitter reserves, and protecting neural tissue from stress-induced oxidative and inflammatory damage. The theoretical framework for adaptogens was formalised in modern pharmacology by Brekhman and Dardymov (1968), but the clinical knowledge that informed their definition had accumulated across centuries in Ayurvedic, Unani, and Traditional Chinese Medicine systems.

At the centre of this project stands Moringa oleifera, widely known as the Miracle Tree. Its leaves have been used therapeutically for over four thousand years, and modern phytochemical analysis has validated why: the leaves contain a concentration of quercetin, kaempferol, chlorogenic acid, isothiocyanates (especially the anti-inflammatory compound moringin), zeatin, all nine essential amino acids, and vitamins A, C, and E that is unmatched [1,12] in the plant kingdom for nutritional and phytomedicinal breadth. Pharmacological studies have confirmed neuroprotective, anti-inflammatory, anxiolytic, and AChE-inhibitory activities that align directly with this project's therapeutic goals.

Seven additional botanicals were selected to complement Moringa's action from different mechanistic angles. Withania somnifera targets the HPA axis through withanolide-mediated CRH suppression and GABA-A potentiation. Bacopa monnieri acts on cholinergic and serotonergic pathways to enhance memory consolidation. Ocimum sanctum modulates monoamine oxidase and corticosterone. Zingiber officinale provides neuroprotection via NF-kB inhibition and enhances systemic bioavailability of co-administered polyphenols through P-glycoprotein inhibition. Mentha piperita activates cognitive alertness through olfactory limbic stimulation.

Citrus limon peel contributes hesperidin-mediated GABAergic anxiolysis and d-limonene-driven cortisol reduction. Glycyrrhiza glabra modulates 11-beta-HSD activity and provides natural sweetening to counterbalance the inherent bitterness of several components.

The delivery vehicle — a dry herbal tea powder for hot water infusion — was chosen deliberately. Hot aqueous extraction is selectively efficient for water-soluble polyphenols, saponins, alkaloids, and flavonoid glycosides that constitute the primary pharmacological agents in this formulation. The tea preparation ritual itself has documented psychophysiological calming effects: the warmth, aroma, and mindful preparation process activate parasympathetic tone, reduce heart rate, and lower cortisol — synergising with the pharmacological activity of the phytoconstituents consumed. The powder format ensures consistent dosing, extended shelf life, and broad demographic accessibility.

1.2 Herbal Tea Powders as a Pharmaceutical Dosage Form

Among the various herbal product categories — capsules, tablets, tinctures, and standardised extracts — dry herbal tea powder blends occupy a historically unique and scientifically underexplored position. They represent the oldest pharmaceutical dosage form in human history, yet remain highly relevant in contemporary nutraceutical science.

From a pharmaceutical technology standpoint, a dry herbal tea powder blend is a solid dosage form requiring assessment of the same parameters as any pharmaceutical powder: particle size distribution, blend uniformity, bulk and tapped density, flow properties, moisture content, and ingredient compatibility. What distinguishes herbal tea powders is that the final therapeutic agent is not the dry powder itself but the aqueous infusion prepared from it — introducing an additional quality consideration: the efficiency and selectivity of phytoconstituent extraction into hot water, and the sensory characteristics of the resulting infusion.For a formulation targeting cognitive and stress outcomes, the infusion preparation step carries an additional psychophysiological dimension. The act of preparing a warm, aromatic herbal beverage is itself a ritualistic behaviour that has been associated in psychoneuroimmunology research with activation of the parasympathetic nervous system, reduction of salivary cortisol and alpha-amylase concentrations, and improvement of self-reported mood, all of which synergise with the pharmacological activity of the phytoconstituents consumed.

1.3 Problem Statement

Despite the substantial body of published evidence supporting the individual efficacy of each of the eight herbs in this formulation, a standardised, multi-herb dry tea powder explicitly designed for the combined therapeutic objectives of stress reduction and cognitive enhancement — with Moringa oleifera as the primary ingredient — has not been documented in the reviewed scientific literature. Commercially available herbal stress teas are predominantly single- or dual-herb products prepared empirically, without systematic physicochemical characterisation, phytochemical standardisation, or stability testing. The present project addresses this gap by applying a systematic pharmaceutical development approach to a traditional wellness concept.

1.4 Scope and Limitations

The scope of this investigation encompasses raw material procurement and processing, formulation development by geometric blending, organoleptic and physicochemical evaluation, qualitative phytochemical profiling, hedonic sensory assessment by a volunteer panel, and a 30-day accelerated stability study. In-vivo pharmacological testing, quantitative HPLC-based phytochemical standardisation, and human clinical trials fall outside the scope of the current project and are identified as priority areas for future research.

2 LITERATURE REVIEW

A thorough literature review was conducted across PubMed, Google Scholar, Scopus, and ScienceDirect databases using botanical names combined with terms such as adaptogen, neuroprotection, stress, anxiety, cognition, memory, HPA axis, and phytochemistry. The following subsections summarise key findings for each botanical with direct relevance to this formulation's therapeutic objectives.

2.1 Moringa oleifera — The Miracle Tree

Taxonomy and Botanical Description: Moringa oleifera Lam. (Family: Moringaceae) is a fast-growing, drought-tolerant deciduous tree of 10 to 12 metres, native to the sub-Himalayan tracts of North-West India and now cultivated across tropical and subtropical Africa, Asia, and Latin America. It is known as Sahjan (Hindi), Murungai (Tamil), Shevga (Marathi), and Drumstick tree (English). The leaves — tripinnate to tetrapinnate with small ovate leaflets — are the primary medicinal and nutritional part used in this formulation.

Phytochemical Composition: Moringa leaf powder contains an extraordinary diversity of secondary metabolites. Glucosinolates and their hydrolysis products — particularly 4-(alpha-L-rhamnopyranosyloxy)-benzyl isothiocyanate (moringin) — are the most pharmacologically distinctive compounds and confer anti-inflammatory, neuroprotective, and pro-apoptotic effects. Flavonoids include quercetin, kaempferol, and rutin; phenolic acids include chlorogenic acid, caffeic acid, and ferulic acid. All nine essential amino acids are present, along with the unique cytokinin zeatin. Published nutritional analyses confirm concentrations of Vitamins A, C, and E substantially exceeding those of reference foods.

Pharmacological Relevance: In-vivo animal studies using the elevated plus maze and open field test have demonstrated anxiolytic effects of Moringa leaf extract comparable to reference anxiolytics at doses of 200 to 400 mg/kg, with simultaneously lower plasma corticosterone concentrations in treated groups. Mechanistically, quercetin and moringin modulate GABA-A receptor activity, inhibit NF-kB-mediated hippocampal neuroinflammation, activate Nrf2-driven antioxidant enzyme upregulation, and inhibit acetylcholinesterase — all mechanistic targets directly relevant to both stress management and cognitive enhancement. [1,12]

2.2 Withania somnifera — Ashwagandha

Botanical Description: Withania somnifera (L.) Dunal (Family: Solanaceae) is a short, erect, branching perennial shrub of 30 to 150 cm with ovate-lanceolate leaves and characteristic small red berries enclosed in papery calyces. It is native to dry regions of India, North Africa, and the Mediterranean, and is commercially cultivated in Rajasthan, Madhya Pradesh, and Gujarat. The root is the primary medicinal part, characterised by an earthy, horse-like odour from which the Sanskrit name 'Ashwagandha' (horse smell) is derived.

Phytochemistry and Pharmacology: Ashwagandha root contains over 40 steroidal lactones called withanolides (withaferin A, withanolide A and D being most studied), sitoindosides VII to X (glycowithanolides), and several alkaloids including withanine and somniferine. [2,14] A landmark randomised controlled trial (Chandrasekhar et al., 2012) [3] documented a 27.9% reduction in serum cortisol, 44% reduction in perceived stress scores, and 22% reduction in Hamilton Anxiety Scale scores following 60-day supplementation. Mechanistically, withanolides suppress CRH secretion from the hypothalamus, potentiate GABA-A receptor sensitivity for anxiolysis without sedation, inhibit acetylcholinesterase to improve cholinergic neurotransmission, and promote hippocampal neuroplasticity by upregulating axonal growth and dendritic proliferation. [2,14]

2.3 Bacopa monnieri — Brahmi

Botanical Description and Traditional Use: Bacopa monnieri (L.) Wettst. (Family: Plantaginaceae) is a small, succulent, creeping herb of marshy habitats, bearing small fleshy leaves and pale purple flowers. Cultivated throughout India, Sri Lanka, and Southeast Asia, it has been used as a medhya rasayana in Ayurveda for over 3,000 years — specifically to enhance intellect, memory, speech, and mental clarity, as documented in the Charaka Samhita. [4,5]

Phytochemistry and Clinical Evidence: The primary bioactives are bacosides A and B — dammarane-type triterpenoid saponins present at 5 to 8% in standardised extracts. They facilitate neuronal repair by stimulating hippocampal kinase activity (promoting new synaptic protein synthesis) and reducing lipid peroxidation of synaptic membranes. A systematic review and meta-analysis (Kongkeaw et al., 2014) [5] confirmed statistically significant improvements in memory acquisition, logical memory, and information processing speed across multiple randomised trials. Effects

are dose-dependent and require 4 to 12 weeks of consistent use for full establishment, consistent with the mechanism of structural synaptic enhancement. [4,5,15]

2.4 Ocimum sanctum — Tulsi (Holy Basil)

Ocimum sanctum L. (Family: Lamiaceae) is a highly aromatic erect herb of 30 to 60 cm bearing ovate-dentate leaves. Its essential oil is characterised by eugenol (60–70%), with additional volatile and non-volatile constituents including ocimumosides A and B — uniquely characterised anti-stress triterpene glycosides not found in other Ocimum species. Animal studies using forced swimming and cold restraint stress models have demonstrated that ocimumosides A and B reduce plasma corticosterone, normalise serotonin and dopamine in the prefrontal cortex and hippocampus, and attenuate adrenal hypertrophy. [6] Eugenol's MAO inhibitory activity elevates synaptic serotonin and dopamine, adding antidepressant and pro-cognitive dimensions. [10] Tulsi also demonstrates significant immunomodulatory activity — particularly relevant given the established immunosuppressive consequences of chronic stress.

2.5 Zingiber officinale — Ginger

Zingiber officinale Roscoe (Family: Zingiberaceae) produces a thick, aromatic rhizome containing phenylalkanones — principally 6-gingerol, 8-gingerol, 10-gingerol, and their dehydration products shogaols and zingerone — and a volatile oil rich in zingiberene and bisabolene. In the neurological context, 6-gingerol inhibits AChE in enzyme kinetics studies and attenuates scopolamine-induced cognitive deficits in animal models. [7] Most importantly for a polyherbal formulation, ginger constituents inhibit intestinal P-glycoprotein efflux transporters, thereby increasing the bioavailability of co-administered polyphenols and saponins. [13] This pharmacokinetic synergy potentially amplifies the effective brain concentrations of bacosides, withanolides, and quercetin beyond levels predicted from individual compound pharmacokinetics.

2.6 Mentha piperita — Peppermint

Mentha piperita L. (Family: Lamiaceae) bears aromatic leaves containing 0.5 to 4% essential oil — characterised by menthol (35–55%), menthone (15–25%), and menthyl acetate (3–10%). Clinical research has consistently demonstrated that peppermint aroma enhances alertness, sustained attention, working memory, and memory quality in healthy adults. [8] The mechanisms involve direct olfactory stimulation of the hippocampus and limbic system through the olfactory bulb pathway, and TRPM8 channel activation by ingested menthol, producing a sensory cooling effect associated with reduced mental fatigue. In the formulation, Peppermint at 5% contributes immediate aromatic appeal and rapid-onset cognitive activation.

2.7 Citrus limon — Lemon Peel Powder

Dried Citrus limon (L.) Burm. f. (Family: Rutaceae) peel concentrates hesperidin, naringenin, tangeretin, nobiletin, and d-limonene. Hesperidin crosses the blood-brain barrier and produces anxiolytic and antidepressant effects through serotonin 5-HT1A modulation and GABA-A potentiation in animal models. D-limonene, the primary volatile constituent, has been shown in clinical aromatherapy studies to reduce salivary cortisol and improve self-reported anxiety and fatigue in participants under work-related stress. Lemon peel also contributes a bright citrus aromatic character that effectively counterbalances the earthy, medicinal notes of Moringa and Ashwagandha, substantially improving overall palatability.

2.8 Glycyrrhiza glabra — Licorice (Mulethi)

Glycyrrhiza glabra L. (Family: Fabaceae) is a perennial herb of 1 to 1.5 metres whose dried roots contain glycyrrhizin (2–15%), the primary bioactive triterpenoid saponin. After oral ingestion, glycyrrhizin is metabolised to 18-beta-glycyrrhetinic acid, which inhibits 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) — the enzyme that converts inactive cortisone to active cortisol in hippocampal and prefrontal cortical tissues. [11] This targeted reduction of local glucocorticoid activity protects hippocampal volume and prevents stress-induced dendritic retraction. Additional flavonoids including isoliquiritigenin provide MAO-B inhibitory and neuroprotective activity. At 8% of the formulation, licorice also functions as a natural sweetener approximately 50 to 100 times sweeter than sucrose, substantially improving tea palatability without added sugars or artificial sweeteners. [11]

4.9 Scientific Basis of Polyherbal Synergy

The concept of polyherbal synergy is supported by multiple pharmacological principles. [16] First, multi-target pharmacology: chronic stress and cognitive decline simultaneously involve HPA axis dysregulation, neurotransmitter imbalances, hippocampal neuroplasticity deficits, neuroinflammation, and oxidative stress — no single herb comprehensively addresses all these pathways. This formulation assigns complementary herbs to each mechanistic domain. Second, pharmacokinetic synergy: ginger's P-gp inhibition enhances intestinal absorption of polyphenols from Moringa, Tulsi, and Lemon peel, effectively increasing brain-accessible concentrations of multiple bioactives. Third, palatability synergy: the bitterness of Brahmi and Ashwagandha is offset by the sweetness of Licorice and the citrus brightness of Lemon peel, making the formulation genuinely pleasant to consume without synthetic additives.

3. AIM AND OBJECTIVES

Primary Aim

To formulate and evaluate a stable, palatable, and phytochemically characterised Moringa-based polyherbal tea powder for the support of stress management and cognitive health, in compliance with applicable pharmaceutical quality standards for herbal preparations.

Specific Objectives

To conduct a comprehensive review of published phytochemical, pharmacognostical, and pharmacological literature on all eight selected botanical ingredients and provide an evidence-based scientific justification for their selection, inclusion, and proportions in the formulation.

To individually process each botanical ingredient through standardised pharmaceutical operations — oven drying at 45°C, size reduction, and sieving through BSS Sieve No. 44 (355 micron) — to achieve uniform particle size before blending.

To prepare the Moringa-based polyherbal tea powder by the geometric dilution blending method, ensuring homogeneous distribution of all eight components.

To perform complete organoleptic evaluation of the formulated powder, assessing colour, odour, taste, texture, and general physical appearance.

To conduct comprehensive physicochemical characterisation, including bulk density, tapped density, Carr's Index, Hausner Ratio, angle of repose, moisture content (LOD), infusion pH, total ash, and acid-insoluble ash.

To perform qualitative phytochemical screening for alkaloids, flavonoids, tannins, saponins, terpenoids, phenolic compounds, steroids, cardiac glycosides, and carbohydrates.

To evaluate the sensory acceptability of the herbal tea infusion using a 9-point hedonic scale with a panel of 25 healthy adult volunteers, assessing colour, aroma, taste, mouthfeel, and overall acceptability.

To conduct a 30-day short-term accelerated stability study at 40°C ± 2°C / 75% ± 5% RH (ICH Q1A(R2)), recording colour, odour, pH, moisture content, and Carr's Index at Day 0, Day 15, and Day 30.

4. PLAN OF WORK

• Literature review on Moringa oleifera and herbs used for stress management and cognitive health.
• Procurement and authentication of herbal ingredients.
• Drying, pulverization, sieving, and formulation of herbal tea powder.
• Preparation of different formulations using varying concentrations of herbs.
• Evaluation of formulations for organoleptic, physicochemical, phytochemical, and antioxidant properties.
• Sensory evaluation and selection of optimized formulation.
• Stability studies of the selected formulation.
• Data analysis, interpretation of results, and report preparation

5. MATERIALS AND METHODS

5.1 Raw Materials — Procurement and Authentication

All eight herbal powders were procured from Kanha Traders (Pune), a certified herbal raw material supplier. Upon receipt, each batch was authenticated against published pharmacopoeial monographs (Indian Pharmacopoeia 2022, Ayurvedic Pharmacopoeia of India) [21,25] by physical characteristic examination (colour, texture, odour) and acceptance of supplier certificates of analysis. Materials not meeting physical characteristic criteria were rejected and reordered.

5.3 Preparation of the Herbal Tea Powder

5.3.1 Pre-processing of Individual Powders

Each herbal powder was processed individually before blending. Moisture reduction: powders with moisture content exceeding 6% were dried in the hot air oven at 45°C for 2 hours. This temperature was deliberately kept below 50°C to prevent thermal degradation of heat-labile volatile oils (Peppermint, Ginger, Tulsi) and steroidal lactones (Ashwagandha). Particle size standardisation: all dried powders were passed through the BSS Sieve No. 44 (355-micron aperture). Fractions passing through the sieve were collected; coarser fractions were discarded. All processed powders were stored in airtight, labelled HDPE containers at 25°C ± 2°C until blending.

 

 

 

5.3.2 Geometric Dilution Blending

The geometric dilution method was employed to achieve homogeneous distribution of all eight components. Blending began with the two smallest-proportion ingredients: Peppermint (5 g) and Lemon peel (5 g) were combined and mixed thoroughly by spatula in a clean, dry glass mortar for 3 minutes. Licorice (8 g) was then added and mixed for 3 minutes. This process continued in ascending order of proportion: Brahmi

 

(10 g), Tulsi (10 g), Ginger (10 g), Ashwagandha (15 g), and finally Moringa (37 g). Each addition was followed by 3 to 5 minutes of thorough mixing. The complete 100 g blend was tumbled in a sealed stainless steel container for 15 minutes to achieve final homogeneity.

5.3.3 Packaging

The final blended powder was filled into UV-protective, food-grade, heat-sealable aluminium foil laminate pouches (100 g per pouch) and sealed immediately using a bench-top impulse heat sealer. Stability study samples were packed as 10 g sub-pouches. All pouches were stored at room temperature (25°C ± 2°C) in a dry location until testing.

5.4 Organoleptic Evaluation

Organoleptic properties were assessed by two trained evaluators working independently under standard laboratory conditions. Colour and appearance were assessed by visual inspection under natural daylight. Odour was evaluated by direct olfaction immediately after opening a sealed pouch. Taste was assessed by dissolving 0.5 g powder in 50 mL warm distilled water and evaluating the cooled infusion. Texture was assessed by rubbing a small quantity between thumb and index finger.

5.5 Physicochemical Evaluation

Bulk Density: Twenty grams of formulated powder was carefully poured through a funnel into a 100 mL graduated measuring cylinder without compaction. The occupied volume was recorded. Bulk Density (g/mL) = Mass / Bulk Volume.

Tapped Density: The cylinder from bulk density was tapped 500 times at 300 taps/minute on the Electrolab apparatus (IP method). Final tapped volume was recorded. Tapped Density (g/mL) = Mass / Tapped Volume.

Carr's Index and Hausner Ratio: Carr's Index (%) = [(Tapped Density – Bulk Density) / Tapped Density] × 100. Hausner Ratio = Tapped Density / Bulk Density. Flow classification: Carr's Index <15% (Excellent), 15–25% (Good), 25–35% (Fair), >35% (Poor).

Angle of Repose: Fixed funnel method: powder was poured through a funnel fixed 10 cm above a flat surface until the cone touched the funnel tip. Height (h) and base radius (r) were measured. Angle of repose (θ) = arctan (h/r).

Moisture Content (Loss on Drying): Approximately 2 g powder was weighed in a pre-tared crucible and dried at 105°C for 3 hours. LOD (%) = [(Initial – Final weight) / Initial weight] × 100. Acceptable limit: <6%.

pH of Aqueous Infusion: One gram of powder was infused in 100 mL of freshly boiled distilled water (90°C) for 5 minutes, filtered through Whatman No. 1 paper, cooled to 25°C, and pH measured with the Hanna HI2211 calibrated with pH 4.0 and 7.0 buffers. Three readings were taken and the average reported.

Total Ash and Acid-Insoluble Ash: Three grams of powder was incinerated in a muffle furnace at 600°C for 4 hours. Total Ash (%) = [Weight of ash / Weight of sample] × 100. Acid-insoluble ash was determined by boiling total ash with 25 mL of 10% HCl for 5 minutes, filtering through ashless filter paper (Whatman No. 41), washing with hot distilled water until neutral, igniting the residue at 600°C, and calculating the percentage.

5.6 Phytochemical Screening

Qualitative phytochemical screening was performed on: (a) an aqueous extract prepared by infusing 5 g powder in 100 mL boiling distilled water for 10 minutes, filtered; and (b) an ethanolic extract prepared by macerating 5 g powder in 50 mL of 70% ethanol for 24 hours with occasional agitation, filtered. Standard tests were performed as described by Khandelwal (2015) [22] and Trease and Evans (2002) [24].

 

 

 

The 30-day accelerated stability data present a consistently reassuring picture of formulation integrity across all evaluated parameters. No parameter showed a change of clinical or pharmaceutical significance between Day 0 and Day 30 under the demanding accelerated storage conditions of 40°C and 75% relative humidity.

Colour: The powder blend remained fundamentally unchanged in colour throughout the study period. The very slight surface darkening noted by one evaluator at Day 30 is consistent with minor Maillard-type non-enzymatic browning reactions between the free amino acids from Moringa and reducing sugars present in multiple botanical components. This surface-level change does not represent degradation of pharmacologically active compounds and would not be perceptible to a consumer examining the bulk product. No colour streaking, fading, or heterogeneous discolouration — indicators of active chemical degradation — was observed at any time point.

Odour: The characteristic herbal-earthy odour remained consistent in both quality and character throughout the study. A marginal reduction in odour intensity noted at Day 30 is attributable to slow volatilisation of the most volatile essential oil components — primarily menthol from Peppermint and zingiberene from Ginger — through the aluminium foil pouch material over 30 days. This minor intensity reduction does not affect the primary non-volatile therapeutic compounds, which constitute the pharmacologically dominant fraction of the formulation.

pH: The infusion pH decreased from 5.83 at Day 0 to 5.74 at Day 30 — a total change of 0.09 pH units over the full study period. This minimal drift is consistent with gradual hydrolysis of ester-bonded polyphenols such as chlorogenic acid (hydrolyses to caffeic acid and quinic acid, both slightly more acidic) under the combined stress of elevated temperature and humidity. A change of less than 0.10 pH units per month is well within acceptable stability limits for any herbal beverage product.

Moisture Content: Moisture content increased from 4.77% at baseline to 5.18% at Day 30, an increase of 0.41 percentage points. This modest rise reflects slow atmospheric moisture ingress through the aluminium foil packaging under 75% RH storage conditions. Critically, the Day 30 moisture content of 5.18% remains comfortably below the 6% safety threshold, confirming that the formulation does not reach problematic moisture levels during the study period under the specified packaging. Based on the rate of increase observed, extrapolation suggests that the 6% threshold would not be approached within 6 months of ambient storage (25°C / 60% RH), though this should be confirmed by a full-duration stability study.

Carr's Index: A corresponding rise in Carr's Index from 19.2% at Day 0 to 20.3% at Day 30 reflects the slightly increased inter-particulate adhesion attributable to the modest moisture uptake. Despite the increase, the Day 30 value of 20.3% remains solidly within the 'good' flow classification range (15 to 25%), confirming that powder handleability and the ability to measure and pour the product for preparation are not compromised at any point during the study.

Overall, the 30-day stability data confirm that the Moringa-based polyherbal tea powder maintains acceptable quality under ICH-compliant accelerated storage conditions when packaged in aluminium foil laminate pouches. The marginal changes across all parameters are consistent with expected behaviour of polyphenol-rich, amino acid-containing botanical blends under thermal and humidity stress, and are well within scientifically and regulatorily acceptable limits.

7. CONCLUSION AND FUTURE RECOMMENDATIONS

This study has accomplished all of its stated objectives, delivering a comprehensively characterised Moringa-based polyherbal tea powder that is scientifically grounded, pharmaceutically evaluated, sensorially appealing, and demonstrably stable across a 30-day ICH-compliant accelerated testing period.

The formulation was constructed on a rational, evidence-based foundation. Each of the eight botanical ingredients was selected based on its documented pharmacological contribution to the dual therapeutic objectives of stress management and cognitive health support. Moringa oleifera, as the primary base ingredient at 37%, provides a broad-spectrum nutritional and phytomedicinal foundation including neuroprotective, anti-inflammatory, and anxiolytic activity through quercetin, kaempferol, moringin, and chlorogenic acid. The seven supporting botanicals address complementary therapeutic targets: HPA axis modulation (Ashwagandha via withanolide-mediated CRH suppression), cholinergic memory enhancement (Brahmi via bacoside-mediated kinase stimulation and AChE inhibition), MAO inhibition and cortisol reduction (Tulsi via eugenol and ocimumosides), neuroprotection and bioavailability enhancement (Ginger via NF-kB inhibition and P-gp inhibition), cognitive alertness through olfactory activation (Peppermint via menthol and TRPM8 activation), GABAergic and serotonergic anxiolysis (Lemon peel via hesperidin), and 11-beta-HSD modulation with natural sweetening (Licorice via glycyrrhizin). Together, these form a multi-target pharmacological strategy that is more comprehensive than any single adaptogen could provide.

 

 

From a pharmaceutical quality perspective, the formulation met all evaluated standards. Powder flow properties (Carr's Index 19.2%, Hausner Ratio 1.24, angle of repose 31.4°) fall within the 'good' classification range, indicating suitability for manufacturing, packaging, and consumer handling. Moisture content (4.77%) and infusion pH (5.83) are within standard limits. Total ash (6.2%) and acid-insoluble ash (0.9%) confirm satisfactory raw material quality. Phytochemical screening confirmed the presence of all expected secondary metabolite classes — alkaloids, flavonoids, tannins, saponins, terpenoids, phenolics, and steroids — with the reassuring absence of cardiac glycosides.

The sensory evaluation outcome — an overall acceptability score of 7.5 out of 9 from 25 untrained volunteers — is particularly significant, demonstrating that the formulation is not merely pharmacologically credible but genuinely pleasant to consume as a daily beverage. Consumer acceptability is the most critical real-world adherence determinant for wellness products, and a score of 7.5 predicts a high probability of consistent voluntary use — precisely what is required for adaptogens and nootropics to deliver their characteristic therapeutic effects.

The 30-day accelerated stability study confirmed no clinically significant deterioration in colour, odour, pH, moisture content, or flow properties under ICH-compliant conditions, providing strong evidence for the product's short-term ambient stability under appropriate aluminium foil laminate packaging.

Recommendations for Future Work

In-vivo pharmacological evaluation: The formulation should be tested in validated chronic restraint stress and scopolamine-induced cognitive deficit animal models to establish pharmacodynamic dose-response and safety at human-equivalent doses.

Quantitative phytochemical standardisation: HPLC-based quantification of withanolide A, bacoside A, quercetin, and glycyrrhizin as marker compounds would enable batch-to-batch quality standardisation.

Full ICH stability study: A 6-month accelerated (40°C/75% RH) and 12-month real-time (25°C/60% RH) study should be conducted to establish a formal shelf life for product registration.

Microencapsulation: Spray-drying of essential oil-rich fractions (Peppermint, Ginger) with a maltodextrin or cyclodextrin carrier would improve long-term volatile stability.

Randomised controlled clinical trial: A double-blind, placebo-controlled trial in adults with mild to moderate perceived stress is the logical final step to establish clinical efficacy for nutraceutical registration.

REFERENCES

1. Anwar F, Latif S, Ashraf M, Gilani AH. Moringa oleifera: A food plant with multiple medicinal uses. Phytotherapy Research. 2007;21(1):17–25.
2. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine. 2000;7(6):463–469.
3. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255–262.
4. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–281.
5. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Scholfield CN. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology. 2014;151(1):528–535.
6. Gupta SK, Prakash J, Srivastava S. Validation of traditional claim of Tulsi, Ocimum sanctum Linn., as a medicinal plant. Indian Journal of Experimental Biology. 2002;40(7):765–773.
7. Zeng GF, Zhang ZY, Lu L, Xiao DQ, Zong SH, He JM. Protective effects of Zingiber officinale on AlCl3-induced learning and memory impairment in rats. Chinese Medical Journal. 2013;126(24):4776–4781.
8. Moss M, Hewitt S, Moss L, Wesnes K. Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang. International Journal of Neuroscience. 2008;118(1):59–77.
9. Hossain MB, Barry-Ryan C, Martin-Diana AB, Brunton NP. Optimisation of accelerated solvent extraction of antioxidant compounds from rosemary (Rosmarinus officinalis L.), marjoram (Origanum majorana L.) and oregano (Origanum vulgare L.). Food Chemistry. 2011;126(1):339–346.
10. Orhan IE, Senol FS. Natural monoamine oxidase inhibitors. In: Farouk A, editor. Monoamine Oxidase Inhibitors. InTech; 2012. p. 83–100.
11. Dhingra D, Parle M, Kulkarni SK. Memory enhancing activity of Glycyrrhiza glabra in mice. Journal of Ethnopharmacology. 2004;91(2–3):361–365.
12. Stohs SJ, Hartman MJ. Review of the safety and efficacy of Moringa oleifera. Phytotherapy Research. 2015;29(6):796–804.
13. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353–356.
14. Singh N, Bhalla M, de Jager P, Gilca M. An overview on Ashwagandha: A rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines. 2011;8(5 Suppl):208–213.
15. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. Journal of Alternative and Complementary Medicine. 2010;16(7):753–759.
16. Bhattacharya A, Muruganandam AV, Kumar V, Bhattacharya SK. Effect of poly herbal formulation on neurochemical perturbations induced by chronic stress. Indian Journal of Experimental Biology. 2002;40(10):1161–1163.
17. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. International Journal of Food Sciences and Nutrition. 2011;62(6):609–616.
18. World Health Organization. WHO monographs on selected medicinal plants. Vol. 1. Geneva: WHO Press; 1999.
19. World Health Organization. Quality control methods for herbal materials. Updated edition. Geneva: WHO Press; 2011.
20. ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A(R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2003.
21. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. Vol. I–III. Ghaziabad, India: IPC; 2022.
22. Khandelwal KR. Practical pharmacognosy: Techniques and experiments. 23rd ed. Pune: Nirali Prakashan; 2015.
23. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 52nd ed. Pune: Nirali Prakashan; 2020.
24. Trease GE, Evans WC. Pharmacognosy. 15th ed. Edinburgh: Saunders (Elsevier); 2002.
25. Gupta AK, Tandon N, Sharma M. Quality standards of Indian medicinal plants. Vol. 2. New Delhi: Indian Council of Medical Research; 2005.